logo

ACIU

AC Immune·NASDAQ
--
--(--)
--
--(--)
3.07 / 10
Netural

AC Immune's fundamental score is 3.07/10, reflecting mixed health. Strengths include a strong gross profit margin at 100% and positive Profit-MV and Cash-MV factors. However, critical efficiency ratios such as Current assets turnover (0.0226) and Fixed assets turnover (1.3315) are underperforming, and several key valuation factors (PB-ROE, Revenue-MV) are rated poorly. This imbalance suggests the company is not efficiently utilizing its assets and may face profitability challenges in the near term.

Fundamental(3.07)SentimentTechnical

Analysis Checks(4/10)

Revenue-MV
Value-0.26
Score1/3
Weight11.33%
1M Return5.20%
Inventory turnover ratio
Value47.85
Score3/3
Weight9.95%
1M Return5.26%
Gross profit margin (%)
Value100.00
Score3/3
Weight22.76%
1M Return10.80%
Profit-MV
Value0.46
Score2/3
Weight16.96%
1M Return7.79%
PB-ROE
Value1.24
Score0/3
Weight7.74%
1M Return3.56%
Current assets turnover ratio
Value0.02
Score0/3
Weight-3.10%
1M Return-1.88%
Fixed assets turnover ratio
Value1.33
Score1/3
Weight-2.69%
1M Return-1.64%
Asset-MV
Value-0.50
Score1/3
Weight20.56%
1M Return8.74%
Cash-MV
Value-0.07
Score2/3
Weight16.98%
1M Return7.73%
Net profit / Total profit (%)
Value100.00
Score0/3
Weight-0.50%
1M Return-0.30%
Is ACIU fundamentally strong?
  • ACIU scores 3.07/10 on fundamentals and holds a Fair valuation at present. Backed by its -64.19% ROE, -2669.70% net margin, -5.12 P/E ratio, 4.02 P/B ratio, and -60.40% earnings growth, these metrics solidify its Netural investment rating.